Trial Profile
Pharmacokinetic and pharmacodynamic study of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 11 Feb 2016 New trial record